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Abstract Brain-derived neurotrophic factor (BDNF) and its
tyrosine kinase receptor TrkB have been reported to be asso-
ciated with poor prognosis in neuroblastoma (NB) patients.
Our previous studies indicated that BDNF activation of
TrkB induces chemo-resistance through activation of
phosphoinositide-3-kinase (PI3K)/Akt pathway. In this study,
we investigated the role of BDNF/TrkB on metastasis in NB.
A tetracycline-regulated TrkB-expressing NB cell line (TB3)
was used. Scratch wound healing assay, Boyden chamber mi-
gration, and invasion assays were performed to study the mi-
gration and invasion of TB3 cells. A tumor xenograft model
using SCID-Beige mice was utilized to detect the metastasis
of NB tumors in vivo. Inhibitors of PI3K, MAPK, Akt, and
mTOR were used. Western blotting was performed to study
the expressions of P-Akt, P-Erk, and P-mTOR. Our results
showed that in TrkB-expressing NB cells, BDNF treatment
significantly increased gap closing (P < 0.01) in scratch
wound healing assay, also significantly enhanced the numbers
of migrating cells (P < 0.01) and invading cells (P < 0.01) in
the Boyden chamber migration and invasion assays. In vivo,
NB distant metastases were significantly increased in mice
with TrkB-expressing xenograft tumors compared to those
with non-TrkB-expressing tumors (P < 0.05). Pre-treatment
with any of the inhibitors for PI3K (LY294002), MAPK
(PD98059), Akt (perifosine), or mTOR (rapamycin) blocked
the BDNF/TrkB-induced increases of cell migration and inva-
sion in TB3 cells, and also blocked the BDNF/TrkB-induced
expressions of P-Akt, P-Erk, and P-mTOR. These data indi-
cated that BDNF/TrkB increased metastasis in NB via
PI3K/Akt/mTOR and MAPK pathways, and BDNF/TrkB
and the downstream targets may be potential targets for the
treatment of NB metastasis.
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Introduction
Neuroblastoma (NB) is one of the most common pediatric
malignancies that derives from neural crest precursor cells. It
is an extracranial solid tumor that most frequently occurs in
adrenal gland [1–2]. Tumor spontaneous regression or differ-
entiation happens in patients with low-risk disease, and sur-
gery with little or no adjunctive therapy is effective for these
patients [2–3]. While for patients with high-risk diseases,
chemo-resistance and metastasis are the two main problems.
Patients may initially response to chemotherapy, but chemo-
resistance would develop soon. Wide metastasis usually oc-
curs at diagnosis. Despite of multimodality chemotherapy and
stem cell transplantation, satisfactory response still could not
be achieved. The long-term survival rate of these patients is
less than 40% [2–5]. So, more effective treatments are urgent-
ly needed.
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Brain-derived neurotrophic factor (BDNF) is a member of
neurotrophin family, and it is known as one of key factors for
the sympathetic nervous system development [2–3]. Previous
reports show that patients with an unfavorable prognosis are
more likely to express BDNF and its tyrosine kinase receptor
TrkB [6–8]. The association between BDNF/TrkB expression
and chemo-resistance in NB has been studied. It was found
that BDNF activation of TrkB induced chemo-resistance in
NB, and that was mainly mediated by PI3K/Akt signaling
pathway. Treatment targeting the PI3K/Akt pathway attenuat-
ed the BDNF/TrkB-induced chemo-resistance [9–14].
Although TrkB expression with invasive capability in NB
has been reported [15–16], a systemic study of the role of
BDNF/TrkB in the NBmetastasis is still needed. In this study,
we provide evidence supporting the hypothesis that
BDNF/TrkB promotes the NB cell metastasis both in vitro
and in vivo. We find that the metastasis potential stimulated
by activation of the BDNF/TrkB pathway in NB cells is
blocked by inhibiting activation of PI3K and MAPK path-
ways. Furthermore, we find that downstream targets of
BDNF/TrkB-stimulated migration and invasion of NB cells
may be Akt and mTOR. All of these results suggest that
BDNF/TrkB and its downstream targets may be the new tar-
gets in the treatment of NB metastasis.
Materials and methods
TrkB-expressing cell line and cell culture A tetracycline
(TET)-regulated TrkB-expressing NB cell line TB3 was uti-
lized. In the presence of TET, TrkB expression is suppressed,
and in the absence of TET, TrkB expression is induced [9].
TB3 cells were cultured in RPMI 1640 (Bioind, Israel) con-
taining 10 % fetal bovine serum (FBS; Bioind, Israel), 2 mM
glutamine, antibiotics, and puromycin (0.5 μg/ml), and in the
presence or absence of tetracycline (1 μg/ml) at 37 °С in 5 %
CO2 incubator.
Reagents Recombinant human BDNF was obtained from
PeproTech, Inc. (Rocky Hill, NJ, USA). Puromycin and tetra-
cycline were purchased from Sigma Chemical Company, Inc.
(St Louis, MO, USA). PI3K inhibitor LY294002, MAPK in-
hibitor PD98059, and mTOR inhibitor rapamycin were pur-
chased from Cell Signaling Technology (Beverly, MA, USA).
Akt inhibitor perifosine was obtained from Selleckchem
(Houston, Texas, USA).
Treatment To repress TrkB expression, TB3 cells were cul-
tured in the presence of tetracycline (1 μg/ml) for 3 days. To
study the blockage of BDNF/TrkB effect, pharmacological
inhibitors, LY294002 (10 μM), PD98059 (10 μM), perifosine
(5 μM), and rapamycin (100 nM), were pre-treated 1 h before
administration of BDNF. TB3 cells were treated with BDNF
(100 ng/ml) for 6 h for the migration and 24 h for the invasion
assays, and treated for 30 h for the scratch wound healing
assays.
Northern analysis Total RNAwas isolated from TB3 cells or
TB3 tumor tissues with RNeasy kit (Qiagen, Dusseldorf,
Germany) following the manufacturer’s protocol. Thirty mi-
crograms of total RNA was electrophoresed in 1 % agarose-
6 % formaldehyde gels containing 2 mg/ml ethidium bromide,
and then blotted to nylon membrane. Hybridization was per-
formed with 32P-labeled insert DNA isolated from a plasmid
containing TrkB.
Scratch wound healing assay TB3 cells were seeded into 24-
well tissue culture plate (Corning, NY, USA). After 48 h of
growth, the confluent monolayer of the cells was scratched
with a 200-μl pipette tip across the center of the well. The
cells were washed with media and treated with BDNF
with/without inhibitors. The pharmacological inhibitors,
LY294002, PD98059, perifosine, and rapamycin, were pre-
treated 1 h before administration of BDNF as described above.
Cell migration was photographed at 10× magnification at 0
and 30 h after treated with BDNF. The wound widths at the
beginning and at the end of the experiments were measured by
Image-Pro Plus software respectively. The cell migration rate
was calculated as (B − E) / B × 100 %, in which B indicates
wound width at the beginning of the experiment, and E indi-
cates wound width at the end of the experiment. The experi-
ments were repeated three times.
Boyden chamber migration and invasion assays The TB3
cells were cultured in 10 % FBS RPMI 1640 media until 60–
70 % confluence. The cells were harvested in 5 % FBS RPMI
1640 media and seeded at 100-μl media of 4 × 104/insert for
migration assay or 8 × 104/insert for invasion assay. The 24-
well Boyden chamber trans-well insert (Corning, NY, USA)
has 8.0-μm-pore polyethylene teraphthalate membrane at the
bottom, which was pre-coated with 30 μl matrigel (BD,
Biosience) (1:3 diluted with plain media) for invasion assay
or left uncoated for migration assay. Bottom wells were fed
with 600 μl of 15 % FBS RPMI 1640 media. BDNF was
placed in the bottom of the well. After 6 or 24 h, the non-
migrating or non-invading cells were removed with cotton-
tipped applicator by scraping the upperside of the insert. The
cells that migrated or invaded to the underside of the insert
were stained using hematoxylin and eosin for 5 and 1 min,
respectively, at room temperature. Photographs of five random
fields were taken, and the number of cells was counted to
calculate the average number of cells per well that had migrat-
ed or invaded. The experiments were repeated three times. In
the experiments using pharmacological inhibitors, LY294002,
PD98059, perifosine, and rapamycin, were placed in the upper
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of the well, and then the assays were conducted as described
above.
Western blotting TB3 cells were treated with inhibitors and
BDNF as described above, then washed twice with cold PBS,
and harvested, and total protein was extracted with Whole
Cell Lysis Assay (KeyGEN BioTECH) following the manu-
facturer’s protocol; 30 μg protein in each condition was load-
ed onto SDS-PAGE gels, transferred to PVDFmembrane, and
probed with the anti-phospho-Akt (P-Akt, Ser473), anti-
phospho-Erk (P-Erk, Thr202/Tyr204), anti-phospho-mTOR
(P-mTOR, Ser2481) antibodies (1:1000 dilution, Cell
Signaling Tech.), or anti-GAPDH antibody (1:10,000 dilution,
Kangchen bio-tech).
In vivo metastasis study TB3 cells were cultured in 10 %
FBS RPMI-1640, harvested, washed with Hank balanced salt
solution (HBSS), and re-suspended in HBSS. A total of 50 μl
of cell suspension containing 4 × 106 TB3 cells were im-
planted into the left gastrocnemius muscle of SCID-Beige
mice aged 4–6 weeks (Taconic, Germantown, NY, USA).
Mice were given water supplemented with placebo (sucrose)
or tetracycline (with sucrose) 1 week before tumor cells injec-
tion, and this was continued throughout the experiment. The
experiment was stopped when the mice reached the ending
criteria (based on their tumor size and whole body status),
and mice were euthanized by asphyxiation with regulated
CO2. Gross metastasis in the brain, chest cavity, and abdom-
inal cavity was evaluated. The adrenal gland, liver, lungs, and
brain were harvested, fixed in 10 % formalin, and used for the
HE staining.
The animal study was approved by the Animal Care and
Use Committee of the National Cancer Institute, and all
mouse treatments, including their housing, were in accordance
with the institutional guidelines (PB-023).
Statistical analysis Comparisons between two groups were
performed using the Student’s t test. The results were shown
as means ± SD. The tumor metastasis in the two groups of
mice was compared by Fisher analysis.
Results
TET-regulated TrkB-expressing cell line
In our study, we used a TET-regulated TrkB-expressing cell
line, TB3. The presence of TET inhibited the TrkB expression,
whereas the absence of TET induced the TrkB expression.
Northern blot was used to study the expression of TrkB in
TB3 cells in the absence or presence of TET. Normally, TB3
cells were cultured in media with TET (1 μg/ml) to inhibit
TrkB expression. To observe the induction of TrkB expression
in TB3 cells, TET was removed from culture media for 1, 2,
and 3 days, and then TB3 cells were harvested. Results
showed that TrkB mRNA level was significantly increased
3 days after TET removal from the culture media (Fig. 1a,
upper panel). A comparison of TrkB expressions in TB3 cells
with or without TET (1 μg/ml, 3 days) was also performed.
The TrkB mRNA level was obviously higher in TB3 cells in
the absence of TET compared to that in the presence of TET
(Fig. 1a, lower panel). So we cultured TB3 cells without TET
for at least 3 days to induce the TrkB expression in our fol-
lowing studies. In our previous study, we have shown that
adding BDNF to the cells could activate the tyrosine kinase,
and further PI3K and MAPK pathways only in the TrkB-
expressing cells (TET−), not the non-TrkB-expressing cells
(TET+) [11]. By using this system, we studied the role of
BDNF/TrkB in the metastasis of NB in vitro and in vivo.
The effect of BDNF/TrkB on the migration and invasion
of NB cells
To study the role of BDNF/TrkB on cells migration, we first
used the scratch wound healing assay. TB3 cells were cultured
in 24-well plates in the presence or absence of TET, and in
each well, a line was scratched with pipette tip until the cells
reached more than 90% confluences and then cells were treat-
ed with BDNF (100 ng/ml) for 30 h. The cell migration rates,
analyzed as described in “Materials and methods” section,
were 39.2 % in control cells and 93.0 % in BDNF-treated
cells. BDNF treatment significantly increased the gap closing
in TrkB-expressing cells (P < 0.01) (Fig. 1b). However, in the
presence of TET (non-TrkB expression), administration of
BDNF to TB3 cells did not significantly change the cell gap
by 30 h (P = 0.67) (Fig. 1b). There was no statistical difference
in closure of cell gaps between TET+ and TET− cells in the
absence of the BDNF treatment (P = 0.51) (Fig. 1b). We also
used the Boyden chamber migration assay to study the
BDNF/TrkB effect on cell migration. TB3 cells were seeded
into the uncoated insert, and cells were treated with BDNF for
6 h in the presence or absence of TET. The cells that migrated
to the underside of the inserts were counted and photographed
(Fig. 1c). The number of migrating cells increased to 1.5-fold
after the BDNF treatment in the TrkB-expressing cells (TET−)
(P < 0.01), while there was no significant change in the num-
ber of migrating cells after the BDNF treatment when TrkB
expression was inhibited (TET+) (Fig. 1c).
The role of BDNF/TrkB in TB3 cell invasion was tested
using a Boyden chamber invasion assay in which the inserts
were coated with matrigel. In the TrkB-expressing cells
(TET−), the invading cell number was 54-fold higher in the
BDNF-treated cells compared to that in the control cells
(P = 0.015) (Fig. 1d). No significant increase of invading cells
was detected after the BDNF treatment in the TrkB-inhibited
cells (TET+) (Fig. 1d). These results suggested that
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BDNF/TrkB increased TB3 cell migration and invasion
in vitro.
TrkB expression inNB xenografts increased themetastasis
in vivo
Next, we investigated the role of BDNF/TrkB in NB me-
tastasis in vivo. SCID-Beige mice were fed chow with or
without TET 1 week before the implantation of TB3 cells
until the end of the experiment to inhibit or induce TrkB
expression. TB3 cells were implanted into the left gastroc-
nemius muscle of SCID-Beige mice. To examine the inhi-
bition or induction of TrkB in vivo, we extracted RNA
from tumor tissues in the leg and detected TrkB levels by
Northern blot, we found that the expression of TrkB
mRNAwas much higher in TET− tumors compared to that
in TET+ tumors (Fig. 2a). The metastasis was checked after
the mice were euthanized, and tumor metastatic sites were
found to be in the adrenal gland, in brain tissue, and in
chest cavity. The metastasis rate in mice with TrkB+ tu-
mors was 55.6 % (10/18 mice), which was much higher
than that in mice with TrkB− tumors (18.2 %, 4/22 mice).
A Fisher analysis showed a significant difference in metas-
tasis between the TrkB+ and TrkB− groups (P = 0.02)
(Table 1). Figure 2b showed the microscopic metastasis
to the adrenal gland and the brain tissues, and Fig. 2c
was the representative mass metastasis around the adrenal
gland. These data indicated that expression of TrkB in xe-
nograft NB tumors was more frequently associated with
disseminated metastatic spread of NB.
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Fig. 1 The roles of BDNF/TrkB in TB3 cell migration and invasion
in vitro. a TET regulated TrkB-expressing cell line. Normally, TB3
cells were cultured with TET (1 μg/ml). To induce the TrkB expression,
TETwas removed from culture media for 1, 2, and 3 days, and then TB3
cells were harvested and Northern blot was performed. A comparison of
TrkB expressions in TB3 cells with or without TET (1μg/ml, 3 days) was
also done. b, c The role of BDNF/TrkB on TB3 cell migration. Scratch
wound healing assay was performed. Cell migration was photographed at
10× magnification at 0 h and 30 h after treated with BDNF. The wound
healing width was measured by Image-Pro Plus software. The cell
migration rate was calculated as described in “Materials and methods”
section. Bars, SD. **P < 0.01, BDNF-treated vs. control (b). Migration
assay was done as described in “Materials and methods” section.
Representative fields of migrating cells under microscope were shown
upper of the figure. The cells that migrated to the underside of the inserts
were counted, and Student’s t test was done. Bars, SD. **P < 0.01,
BDNF-treated vs. control (c). d The role of BDNF/TrkB on cell
invasion. Invasion assay was performed as described in “Materials and
methods” section. Representative fields of invading cells under
microscope were shown upper of the figure. The cells that invaded to
the underside of the inserts were counted, and Student’s t test was done.
Bars, SD. **P < 0.01 BDNF-treated vs. control. The experiments were
repeated three times
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PI3K and MAPK pathways mediated
the BDNF/TrkB-induced increases of cell migration
and invasion
We and others previously reported that binding of TrkB and
BDNF activates PI3K and MAPK pathways [9–14]. Having
found that BDNF/TrkB increased the migration and invasion
in vitro and metastasis in vivo, we next investigated the path-
way(s) that mediated the BDNF/TrkB-increased metastasis by
using pharmacological inhibitors. TB3 cells cultured in the
absence of TET were pre-treated with PI3K inhibitor
LY294002, or MAPK inhibitor PD98059 for 1 h, and then
treated with BDNF for 30 h in scratch wound healing assay,
for 6 h in the Boyden chamber migration assay, and for 24 h in
Boyden chamber invasion assay.
The result from scratch wound healing assay showed that
the cell migration rates were 54.9 % in the control cells,
93.0 % in the BDNF-treated cells, 54.9 % in the BDNF +
LY294002-treated cells, and 62.2 % in the BDNF +
PD98059-treated cells (Fig. 3a). BDNF-induced increase of
gap closing was blocked by either LY294002 (P < 0.01) or
PD98059 (P < 0.01) in TB3 cells (Fig. 3a). We also used the
Boyden chamber migration assay to study the pathway(s) that
mediated the BDNF/TrkB-increased TB3 cell migration. The
Boyden chamber migration assay was done as described in
“Materials and methods” section. The cells that migrated to
the underside of the inserts were counted and photographed
(Fig. 3b). BDNF-induced increase of migrating cells was re-
duced by pre-treatment with either LY294002 (P < 0.05) or
PD98059 (P < 0.05) (Fig. 3b).
The pathway(s) that mediated the BDNF/TrkB-increased
TB3 cell invasion was tested using a Boyden chamber inva-
sion assay. The Boyden chamber invasion assay was done as
described in “Materials and methods” section. The cells that
invaded to the underside of the inserts were counted and
photographed (Fig. 3c). BDNF-induced increase of invading
cells was reduced by pre-treatment with either LY294002
(P < 0.01) or PD98059 (P < 0.01) (Fig. 3c).
We observed the effects of LY294002 and PD98059 on P-
Akt(Ser473) and P-Erk(Thr202/Tyr204) expressions by
Western blotting. The results showed that the BDNF/TrkB-
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Fig. 2 The roles of BDNF/TrkB in NB tumor metastasis in vivo. a TET
regulated TrkB expression in vivo. Xenograft NB tumor tissues were
harvested from SCID-Beige mice, which were fed with or without TET.
Animal model was described in “Materials and methods” section. RNA
was extracted from the tumor tissues, and TrkB expression was detected
byNorthern blot. b, cMetastasis of NB tumors in vivo. The adrenal gland
and brain of mice with or without metastasis were demonstrated after HE
staining (4× and 20× magnifications for the adrenal glands, and 20× and
60× magnifications for brain tissues) (b). A representative metastatic
tumor around the adrenal gland was shown (c)
Table 1 Comparison of metastasis between TrkB-expressing tumors
and non-TrkB-expressing tumors
Group Metastasis(+) Metastasis(−) Total Ratio of metastasis (%)
TrkB(+) 10 8 18 55.6
TrkB(−) 4 18 22 18.2
Total 14 26 40 35
Fisher’s test: P = 0.02
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LY294002, while PD98059 did not inhibit the expression of
P-Akt (Fig. 3d). And the BDNF/TrkB-induced increase of P-
Erk(Thr202/Tyr204) was blocked by PD98059, while
LY294002 did not inhibit the expression of P-Erk(Thr202/
Tyr204) (Fig. 3d).
These data indicated that both PI3K pathway and MAPK
pathway mediated BDNF/TrkB effect on TB3 cell migration
and invasion.
Akt and mTOR mediated the BDNF/TrkB-induced
increases of cell migration and invasion
As we have reported that the PI3K/Akt signal transduction
pathway mediated the BDNF/TrkB-induced chemo-
resistance in NB [9–11], and this study showed that the
PI3K pathway also mediated the BDNF/TrkB-increased mi-
gration and invasion, we further studied whether or not Akt
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Fig. 3 The signal transduction pathways that mediate BDNF/TrkB
effects on cell migration and invasion. a TB3 cells cultured in the
absence of TET were scratched with a 200-μl pipette tip across the
center of the well, and then cells were pre-treated with PI3K inhibitor
LY294002 or MAPK inhibitor PD98059 for 1 h followed by the BDNF
treatment for 30 h. Gap closing was photographed. The cell migration rate
was calculated as described in “Materials and methods” section. Bars,
SD. **P < 0.01, BDNF-treated vs. control. ##P < 0.01, LY294002 pre-
treated or PD98059 pre-treated vs. BDNF-treated. bMigration assay was
performed as described in the “Materials and methods” section.
Representative fields of migrating cells under microscope were shown
upper of the figure. The cells that migrated to the underside of the inserts
were counted, and Student’s t test was done. Bars, SD. **P < 0.01,
BDNF-treated vs. control. #P < 0.05, LY294002 pre-treated or
PD98059 pre-treated vs. BDNF-treated. c Invasion assay was
performed as described in the “Materials and methods” section.
Representative fields of invading cells under microscope were shown
upper of the figure. The cells that invaded to the underside of the inserts
were counted, and Student’s t test was done. Bars, SD. **P < 0.01,
BDNF-treated vs. control. ##P < 0.01, LY294002 pre-treated or
PD98059 pre-treated vs. BDNF-treated. d TB3 cells were pre-treated
with PI3K inhibitor LY294002 or MAPK inhibitor PD98059 for 1 h
followed by the BDNF treatment for 1 h, and then harvested. Total
protein was extracted for Western blotting
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and its downstream targets mTOR were involved in
BDNF/TrkB-induced increases of cell migration and invasion.
We pre-treated TB3 cells with Akt inhibitor perifosine or
mTOR inhibitor rapamycin for 1 h, and then treated with
BDNF for 30 h in scratch wound healing assay, 6 h in
Boyden chamber migration assay, or 24 h in Boyden chamber
invasion assay. The result from the scratch wound healing
assay showed that the cell migration rates were 54.9 % in
the control cells, 85.3 % in the BDNF-treated cells, 51.6 %
in the BDNF + perifosine-treated cells, and 59.3 % in the
BDNF + rapamycin-treated cells (Fig. 4a). BDNF-induced
increase of gap closing was blocked by either perifosine
(P < 0.01) or rapamycin (P < 0.01) in TB3 cells (Fig. 4a).
For the cell migration evaluated by the Boyden chamber
migration assay, we found that BDNF-induced increase
of migrating cells was reduced by pre-treatment with
either perifosine (P < 0.01) or rapamycin (P < 0.01)
(Fig. 4b). For the cell invasion evaluated by the
Boyden chamber invasion assay, we found that BDNF-
induced increase of invading cells was also reduced by
pre-treatment with either perifosine (P < 0.01) or
rapamycin (P < 0.01) (Fig. 4c).


























































































































Fig. 4 The molecular targets that mediate BDNF/TrkB effects on TB3
cell migration and invasion in vitro. a TB3 cells cultured in the absence of
TETwere scratched with a 200-μl pipette tip across the center of the well;
then cells were pre-treated with Akt inhibitor perifosine, or mTOR
inhibitor rapamycin for 1 h followed by the BDNF treatment for 30 h.
Gap closing was photographed. The cell migration rate was calculated as
described in “Materials and methods” section. Bars, SD. **P < 0.01,
BDNF-treated vs. control. ##P < 0.01, Akt or mTOR pre-treated vs.
BDNF-treated. b Migration assay was performed as described in the
“Materials and methods” section. Representative fields of migrating
cells under microscope were shown upper of the figure. The cells that
migrated to the underside of the inserts were counted, and Student’s t test
was done. Bars, SD. **P < 0.01, BDNF-treated vs. control. ##P < 0.01,
Akt or mTOR pre-treated vs. BDNF-treated. c Invasion assay was
performed as described in the “Materials and methods” section.
Representative fields of invading cells under microscope were shown
upper of the figure. The cells that invaded to the underside of the inserts
were counted, and Student’s t test was done. Bars, SD. **P < 0.01,
BDNF-treated vs. control. ##P < 0.01, Akt or mTOR pre-treated vs.
BDNF-treated. d TB3 cells were pre-treated with Akt inhibitor
perifosine, or mTOR inhibitor rapamycin for 1 h followed by the
BDNF treatment for 1 h, and then harvested. Total protein was
extracted for Western blotting
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We also observed the effects of perifosine and rapamycin
on P-Akt(Ser473) and P-mTOR(Ser2481) expressions by
Western blotting. The results showed that the BDNF/TrkB-
induced increase of P-Akt(Ser473) was blocked by perifosine,
while rapamycin did not inhibit the expression of P-Akt
(Fig. 4d). And the BDNF/TrkB-induced increase of P-
mTOR(Ser2481) was blocked by both perifosine and
rapamycin (Fig. 4d).
These data indicated that both Akt and mTOR mediated
BDNF/TrkB effect on TB3 cell migration and invasion.
Discussion
In the present study, we indentified that BDNF/TrkB increased
TB3 cell metastasis in vitro and in vivo. Inhibitors of PI3K
pathway, MAPK pathway, Akt, and mTOR blocked the
BDNF/TrkB-increased cell migration and invasion in vitro.
BDNF is needed for the development and mainte-
nance of peripheral sympathetic and neural crest-
derived sensory neurons [17–19]. Binding of BDNF to
its tyrosine kinase receptor TrkB activates PI3K,
MAPK, and PLC-γ pathways [9, 17–18]. BDNF/TrkB
has been reported to be highly expressed in many ma-
lignancies and associated with poor prognosis [20–24].
In NB, BDNF/TrkB expressions were found in tumors
of patients with unfavorable prognosis [6], and
BDNF/TrkB promoted NB cell survival and prolifera-
tion, and induced resistance to chemo-therapy in vitro
and in vivo [25–27]. Our previous studies have indicat-
ed that BDNF/TrkB induced chemo-resistance via
PI3K/Akt pathway and MAPK pathway [9–11]; we
and others have reported that inhibition of TrkB en-
hanced chemotherapeutic efficacy in NB in vitro and
in vivo [13, 28]. Studies also found that BDNF/TrkB
increased metastasis in many malignancies, such as pan-
creatic ductal carcinoma [29], prostate cancer [30], lung
cancer [31], hepatocellular carcinoma [21, 32], colorec-
tal cancer [33–34], gastric cancer [35], choriocarcinoma
[36], ovarian cancer [37], and multiple myeloma [38].
Some of these reports showed that blocking TrkB or
BDNF suppressed the BDNF/TrkB-induced metastasis
[21, 34, 36]. Studies have shown that BDNF/TrkB me-
diated NB cell invasiveness, and Douma S. and Geiger
TR. et al. studied the mechanisms of BDNF/TrkB-in-
duced cell invasiveness [15–16, 39–40]. Douma S.
et al. reported that TrkB increased rat intestinal epithe-
lial (RIE) cell aggressiveness via suppression of anoikis
(apoptosis resulting from loss of cell-matrix interac-
tions), and their results showed that TrkB activated
PI3K/PKB signaling, which contributed to anoikis resis-
tance [39]. Geiger TR et al. showed that TrkB increased
NB cell aggressiveness via suppression of anoikis;
further, they identified that kinase activity, but not ad-
hesion domains, was required for TrkB-induced anoikis
suppression in vitro and tumor metastatic capacity
in vivo [40]. But further mechanisms have not been
shown in their reports. Hecht M. et al. focused their
studies on HGF (hepatocyte growth factor) and its re-
ceptor c-Met, and their results showed that TrkB up-
regulated HGF and c-Met expression to promote NB
cell invasive capability [15]. Cimmino F. et al. studied
the role of galectin-1 in TrkB-mediated invasiveness in
NB cells. They found that activation of TrkB up-
regulated galectin-1 expression, and knockdown of
galectin-1 mRNA expression or use galectin-1 inhibitor
reduced the migratory and invasive capacity of NB cells
[16]. In our present study, we explored the role of
BDNF/TrkB in NB cell metastasis in vitro and in vivo
and further studied the pathways that mediated
BDNF/TrkB effect on NB cell migration and invasion.
Our results showed that BDNF activation of TrkB
increased the TB3 cell migration and invasion in vitro,
and metastasis was significantly increased in TrkB-
expressing TB3 tumors compared to that in non-TrkB-
expressing TB3 tumors in vivo. These results were sim-
ilar to Mineyoshi Aoyama and others’ reports in which
BDNF/TrkB promoted NB cell invasive activity [6,
15–16, 40]. Although there are studies that focus on
the mechanisms of BDNF/TrkB-mediated NB cell me-
tastasis [15–16, 40], the signal transduction pathways
that mediated the invasive activity were not fully inves-
tigated. Douma S. et al. have reported that TrkB acti-
vated PI3K/PKB signaling, which contributed to anoikis
resistance in RIE cells [39]. In our present study, we
found that suppression of PI3K and MAPK pathways
inhibited BDNF/TrkB-increased migration or invasion
in TB3 cells, and blocked BDNF/TrkB-induced increase
of P-Akt(Ser473) and P-Erk(Thr202/Tyr204) (Fig. 3a–d).
Furthermore, inhibitors for Akt and mTOR, two down-
stream targets in PI3K pathway [26], could also block
BDNF/TrkB-increased cell migration and invasion, and
blocked BDNF/TrkB-induced increase of P-Akt(Ser473)
and P-mTOR(Ser2481) (Fig. 4a–d). Our results showed
that inhibitor of mTOR (rapamycin) suppressed the
BDNF/TrkB-increased migration and invasion in TB3
cells. This result is differed from Douma S.’s study in
which rapamycin did not contribute to TrkB-mediated
anoikis resistance in RIE cells [39]. These may suggest
that although mTOR is not involved in TrkB-mediated
anoikis resistance in RIE cells, it may involve in other
key processes during NB cell migration and invasion.
Further studies are needed to explain this.
Epithelial mesenchymal transition (EMT) is the conversion
of epithelial cells to mesenchymal cells, which is considered
to be associated with an increase of cell migration and
16234 Tumor Biol. (2016) 37:16227–16236
invasion capacity, as well as resistance to anoikis/apoptosis.
EMT was reported to be accompanied by an increase of N-
cadherin and Slug, or by a decrease of E-cadherin [41]. In our
present study, we investigated the expressions of N-cadherin,
E-cadherin, and Slug under the BDNF treatment. We found
that the BDNF treatment of TrkB-expressing TB3 cells in-
creased E-cadherin expression, decreased Slug expression,
but had no effect on N-cadherin expression within the time
points we tested (Suppl. Fig. 1). Inhibitors for PI3K, MAPK,
Akt, andmTOR could individually attenuate the BDNF/TrkB-
induced increase of E-cadherin or decrease of Slug. These
inhibitors had no effect on N-cadherin expression (Suppl.
Fig. 2). As our results are different from some reports [41],
so further studies are needed to investigate whether or not E-
cadherin and Slug are involved in the BDNF/TrkB-induced
migration or invasion, and if they are, how do they affect the
migration and invasion? Recent reports show that EMT is not
required for metastasis in breast cancer and pancreatic cancer
[42, 43], so the role of EMT during metastasis in different
types of cancers may vary.
Our study provided evidence that BDNF/TrkB increased
migration and invasion of TB3 cells through PI3K/Akt and
MAPK pathways; together with previous studies that
BDNF/TrkB mediated chemo-resistance through PI3K/Akt
pathway in the treatment of NB patients [9–14], we believe
that BDNF/TrkB and its downstream targets will play very
important roles in the treatment of high-risk NB patients,
who are suffering from metastasis or/and chemo-resistance.
Also, there are some limitations in our present study, such as
no validation of the results in clinical tumor samples, only one
cell line used, and no more inhibitors targeting BDNF/TrkB
signaling pathways. In the future, we will try to finish these
studies to fully elucidate the effect of BDNF/TrkB on NB
metastasis.
Above all, our study showed that BDNF/TrkB increased
TB3 cell migration and invasion through PI3K/Akt/mTOR
and MAPK pathways. Based on these findings, we may pro-
vide new potential molecular targets for the treatment of NB
metastasis.
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